Max Dawson is an adviser on business development. Max has over 20 years of industry experience, 15 of which is in business development, finance, and operations. He has played leadership roles in young and startup companies including CFO of DermBiont, VP of Finance and Operations at Pellepharm, and VP of Business Development at Adagene. Before working with startup companies, Max was the head of the licensing division at Dyax Corp, and he has negotiated and closed over 50 therapeutic transactions. He has also worked in Finance at Vertex Pharmaceuticals and Merck KGaA. Max started his career as a bench scientist at Vertex Pharmaceuticals. He holds an MBA from the F.W. Olin School of Business, where he has also guest lectured, and an undergraduate degree from Bates College.